Compare EHang Holdings Ltd - ADR (EH) vs TG Therapeutics Inc (TGTX) Price & Performance

EHang Holdings (EH) trades at $5.70, up 0.18% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, with a net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid a volatile year for air taxi stocks.

The outlook remains speculative, with significant growth potential in the advanced air mobility market offset by persistent losses and competitive pressures. Risks include execution hurdles and funding needs, while analyst sentiment is divided with a consensus price target of $6.97 suggesting modest upside from current levels.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.